BamSEC and AlphaSense Join Forces
Learn More

Ikena Oncology Inc.

NASDAQ: IKNA    
Share price (12/23/24): $1.67    
Market cap (12/23/24): $80.6 million
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 311 pages Agreement and Plan of Merger Among: Ikena Oncology, Inc.; Insight Merger Sub I; Insight Merger Sub II; and Inmagene Biopharmaceuticals Dated as of December 23, 2024
12/34/56
EX-2.1
from 8-K 96 pages Agreement and Plan of Merger Among: Ikena Oncology, Inc.; Portsmouth Merger Sub I, Inc; Portsmouth Merger Sub II, LLC; Pionyr Immunotherapeutics, Inc. and Fortis Advisors LLC, as the Securityholder Agent Dated as of August 4, 2023
12/34/56
EX-2.2
from S-1 60 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Agreement and Plan of Merger by and Among Ikena Oncology, Inc. Ami Merger Sub, Inc. Amplify Medicines, Inc. and Atlas Venture Fund XI, L.P. as Stockholder Representative
12/34/56
EX-2.1
from S-1 58 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Agreement and Plan of Merger by and Among Kyn Therapeutics Inc., Arrys Merger Sub, Inc., Arrys Therapeutics, Inc. and Orbimed Private Investments VI, LP as Stockholder Representative
12/34/56
EX-2.2
from DRS/A 60 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Agreement and Plan of Merger by and Among Ikena Oncology, Inc. Ami Merger Sub, Inc. Amplify Medicines, Inc. and Atlas Venture Fund XI, L.P. as Stockholder Representative
12/34/56
EX-2.1
from DRS/A 58 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Agreement and Plan of Merger by and Among Kyn Therapeutics Inc., Arrys Merger Sub, Inc., Arrys Therapeutics, Inc. and Orbimed Private Investments VI, LP as Stockholder Representative
12/34/56